TY - JOUR
T1 - Tumour dissemination in multiple myeloma disease progression and relapse
T2 - A potential therapeutic target in high-risk myeloma
AU - Zeissig, Mara N.
AU - Zannettino, Andrew C.W.
AU - Vandyke, Kate
N1 - Funding Information:
Funding: M.N.Z. was supported by Chun Chung Wong and So Sau Lam Memorial Postgraduate Cancer Research Top-Up Scholarship from the Florey Medical Research Foundation, a Short-Term Research Grant from the German Academic Exchange Service (DAAD) and a Hans-Jürgen and Marianne Ohff Research Grant from the University of Adelaide. K.V. was supported by an Early Career Cancer Research Fellowship from the Cancer Council SA Beat Cancer Project on behalf of its donors and the State Government of South Australia through the Department of Health.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Multiple myeloma (MM) is a plasma cell (PC) malignancy characterised by the presence of MM PCs at multiple sites throughout the bone marrow. Increased numbers of peripheral blood MM PCs are associated with rapid disease progression, shorter time to relapse and are a feature of advanced disease. In this review, the current understanding of the process of MM PC dissemination and the extrinsic and intrinsic factors potentially driving it are addressed through analysis of patient-derived MM PCs and MM cell lines as well as mouse models of homing and dissemination. In addition, we discuss how patient cytogenetic subgroups that present with highly disseminated disease, such as t(4;14), t(14;16) and t(14;20), suggest that intrinsic properties of MM PC influence their ability to disseminate. Finally, we discuss the possibility of using therapeutic targeting of tumour dissemination to slow disease progression and prevent overt relapse.
AB - Multiple myeloma (MM) is a plasma cell (PC) malignancy characterised by the presence of MM PCs at multiple sites throughout the bone marrow. Increased numbers of peripheral blood MM PCs are associated with rapid disease progression, shorter time to relapse and are a feature of advanced disease. In this review, the current understanding of the process of MM PC dissemination and the extrinsic and intrinsic factors potentially driving it are addressed through analysis of patient-derived MM PCs and MM cell lines as well as mouse models of homing and dissemination. In addition, we discuss how patient cytogenetic subgroups that present with highly disseminated disease, such as t(4;14), t(14;16) and t(14;20), suggest that intrinsic properties of MM PC influence their ability to disseminate. Finally, we discuss the possibility of using therapeutic targeting of tumour dissemination to slow disease progression and prevent overt relapse.
KW - Dissemination
KW - Metastasis
KW - Multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=85097251506&partnerID=8YFLogxK
U2 - 10.3390/cancers12123643
DO - 10.3390/cancers12123643
M3 - Review Article
C2 - 33291672
AN - SCOPUS:85097251506
VL - 12
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 12
M1 - 3643
ER -